ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare ConferenceBusiness Wire • 11/02/23
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian CancerBusiness Wire • 10/27/23
ImmunoGen (IMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 10/26/23
Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength?Zacks Investment Research • 10/25/23
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating ResultsBusiness Wire • 10/19/23
Wall Street Analysts Think ImmunoGen (IMGN) Could Surge 49.11%: Read This Before Placing a BetZacks Investment Research • 10/04/23
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian CancerBusiness Wire • 09/28/23
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial OfficerBusiness Wire • 09/18/23
ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?Seeking Alpha • 08/29/23
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in JapanBusiness Wire • 08/28/23